Over a decade of national health data, the United States has watched its chronic kidney disease burden hold eerily still at roughly one in seven adults — yet beneath that stillness, a quiet transformation has unfolded. Diabetes-driven kidney disease has surged by nearly a third, even as new protective therapies entered the market, suggesting that medicine's capacity to treat is being outpaced by society's capacity to generate illness. The findings, published in the New England Journal of Medicine, point toward a deeper reckoning: kidney disease is no longer a solitary condition but a node in a
Diabetes-linked kidney disease surges despite new treatments, study finds
Chronic kidney disease increases risk of heart attacks, strokes, kidney failure, and early death; disproportionately affects Black Americans at nearly 1-in-5 prevalence.
Kidney disease no longer travels alone.
Mark
Why would new kidney-protective drugs fail to move the needle on overall disease rates?
Mimi
The drugs work for people who take them and tolerate them well. But the study suggests either that not enough people are accessing these treatments, or that new cases of diabetes-related kidney disease are emerging faster than existing cases are being prevented. It's a gap between what the medicine can do and what's actually happening in the population.
Mark
The shift toward diabetes-linked kidney disease—is that because diabetes itself is increasing?
Mimi
Likely, yes. But it's also a composition shift. Non-diabetes kidney disease stayed flat. So we're not seeing more kidney disease overall; we're seeing the disease increasingly tied to metabolic dysfunction. That's the concerning part.
Mark
You mentioned cardiovascular-kidney-metabolic syndrome. What does that actually mean for a patient?
Mimi
It means their kidneys, heart, and metabolic system are failing together. A person might come in with high blood pressure and think it's just a heart problem. But their kidneys are already damaged. Their diabetes is worsening. You can't fix one without addressing all three.
Mark
The disparities by race and education—are those new findings?
Mimi
The racial disparity isn't new. Black Americans have always carried a higher burden of kidney disease. What's new is that the education gap widened. That tells us social determinants matter as much as genetics. Poverty, access to care, stress—these shape who gets sick.
Mark
So what happens next? What does the field do with this information?
Mimi
The honest answer is we don't yet know. The study is a warning. It says the current approach isn't working. We need better prevention, earlier detection, and probably different treatment strategies that address the whole metabolic picture, not just the kidneys.
Le Pouls
- Diabetes-related kidney disease climbed 30% over ten years — from 4.7% to 5.7% of American adults — even as the overall CKD rate refused to budge from roughly 15%.
- Two newly approved kidney-protective therapies, SGLT2 inhibitors and finerenone, failed to move the needle on population-level disease rates, raising urgent questions about treatment gaps and who is actually receiving care.
- Black Americans bear a disproportionate toll — nearly one in five carries chronic kidney disease — with no meaningful improvement recorded across the entire decade.
- The educational attainment gap in CKD widened over the study period, and kidney disease rates in men crept upward while women's rates held flat, signaling that social determinants are actively shaping who gets sick.
- Researchers are reframing the problem entirely, describing an emerging cardiovascular-kidney-metabolic syndrome that demands multi-system clinical approaches rather than organ-by-organ treatment.
Over a decade of national health data, the United States has watched its chronic kidney disease burden hold eerily still at roughly one in seven adults — yet beneath that stillness, a quiet transformation has unfolded. Diabetes-driven kidney disease has surged by nearly a third, even as new protective therapies entered the market, suggesting that medicine's capacity to treat is being outpaced by society's capacity to generate illness. The findings, published in the New England Journal of Medicine, point toward a deeper reckoning: kidney disease is no longer a solitary condition but a node in an interconnected web of metabolic, cardiovascular, and social failure that no single drug can untangle.
Chronic kidney disease is common enough that roughly one in seven American adults carries it — and most of them don't know. The disease is silent until it isn't, until a heart attack or stroke or sudden organ failure announces what had been quietly building for years. What a new decade-long study reveals is that while the overall prevalence of CKD has flatlined at around 15%, the composition of that disease has shifted in a troubling direction.
Analyzing more than 25,000 adults through the National Health and Nutrition Examination Survey, researchers found that diabetes-linked kidney disease rose from 4.7% to 5.7% of Americans between 2013 and 2023 — a relative increase of roughly 30%. This happened even as two new kidney-protective medications, SGLT2 inhibitors and finerenone, entered the market and received approval specifically to reduce kidney failure risk. The overall burden did not improve.
The disease does not distribute evenly. Black Americans carry nearly a one-in-five prevalence, substantially higher than white Americans, with no meaningful change over the study period. The gap between higher and lower educational attainment widened across the decade. Kidney disease in men appears to be rising while women's rates hold steady — patterns that implicate social and economic circumstances as forcefully as biology.
What the findings ultimately describe is a disease that no longer travels alone. The connections between kidney disease, heart failure, and diabetes are deepening, and researchers now speak of cardiovascular-kidney-metabolic syndrome — an acknowledgment that treating a single organ in isolation is no longer sufficient. The kidneys are failing as part of a broader metabolic unraveling, and the central question the study leaves open is a sobering one: if the best available therapies haven't slowed the tide, what will it actually take to turn it?
Chronic kidney disease moves through the body like a thief in the night. Most people who have it don't know. They feel fine until the moment they don't—until their heart seizes, or a stroke hits, or their kidneys simply stop working. The disease is common enough that roughly one in seven American adults carries it. What's striking is that this number hasn't budged in a decade. In 2013, about 15% of U.S. adults had chronic kidney disease. In 2023, still about 15%. The prevalence has flatlined. But the composition of that disease has shifted in a troubling direction.
Researchers analyzing ten years of data from the National Health and Nutrition Examination Survey—a rolling government study that brings representative samples of Americans to exam centers for blood work, urine tests, and physical measurements—found that diabetes-related kidney disease has surged while non-diabetes kidney disease has held steady. The proportion of Americans with kidney disease driven by diabetes climbed from 4.7% to 5.7%, a relative increase of roughly 30%. It's a meaningful shift in the disease landscape, and it arrived despite the introduction of new medications specifically designed to protect the kidneys. SGLT2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, both entered the market during this decade-long window. Both were approved to reduce the risk of kidney failure. Yet overall kidney disease rates remained stagnant.
The study, which examined records of more than 25,000 adults aged 20 and older, used two standard kidney tests to identify disease. One measures how efficiently the kidneys filter waste from the blood. The other detects whether protein is leaking into the urine—a sign the kidney's filtering system is breaking down. Anyone with abnormal results on either test was classified as having chronic kidney disease. The researchers then tracked how rates changed across demographic groups: by age, sex, race, ethnicity, income, and the presence of conditions like diabetes, high blood pressure, obesity, and heart disease.
What emerged was a picture of disease that doesn't distribute evenly. The gap between people with higher and lower educational attainment widened over the decade, suggesting that social and economic circumstances—not biology alone—determine who develops kidney disease. Kidney disease in men appears to be creeping upward, while rates in women have remained flat. And Black Americans continue to carry a disproportionate burden: nearly one in five has chronic kidney disease, substantially higher than white Americans, with no meaningful improvement over the ten-year span.
The shift toward diabetes-linked kidney disease points to something larger. Kidney disease no longer travels alone. About one in four Americans with heart disease also has chronic kidney disease, and the connections between kidney disease, heart failure, and diabetes are strengthening, not weakening. Researchers now describe this interconnected pattern as cardiovascular-kidney-metabolic syndrome—a recognition that treating a single organ in isolation is no longer adequate. The kidneys are failing not as an isolated problem but as part of a broader metabolic collapse. This finding, published in the New England Journal of Medicine, raises an urgent question: if new therapies designed to protect the kidneys haven't slowed the overall disease burden, what will it take to reverse course?
Citations marquantes
Despite these advancements, overall CKD rates have remained stagnant. This finding underscores the urgent need for further research and intervention to address the escalating burden of CKD in the context of diabetes.— Ashish Verma, assistant professor of medicine at Boston University Chobanian & Avedisian School of Medicine
What we're seeing is that kidney disease no longer travels alone. About one in four Americans with heart disease also has CKD, and the links between kidney disease, heart failure, and diabetes are getting stronger, not weaker.— Sophie Claudel, clinical instructor of nephrology at Boston University and nephrology resident at Boston Medical Center
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗
Health & Medicine